GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma Q2 FY27 Net Profit Rises 32.5% YoY to ₹1,124 Cr

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 08:05 PM IST  ·  BSE ID: 1aa86da3-5aac-41ab-9de5-466dc552bfcd
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's latest quarterly results show profits grew by 32.5% and revenue increased by 23.9%, alongside a key acquisition.
🤖 AI Summary
  • Aurobindo Pharma reported Q2 FY27 Net Profit of ₹1,124 Cr, marking a 32.5% growth year-on-year.
  • Revenue from operations for Q2 FY27 increased 23.9% year-on-year to ₹10,263 Cr.
  • EBITDA reached its highest-ever quarterly figure of ₹2,156 Cr, achieving a 21.0% margin.
  • The acquisition of Lannett was completed, expanding US presence and capabilities in complex substances.
  • Generated net cash flow of US$ 146 million in the quarter, with a net cash position of ~US$ 189 million as on September 30, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
₹ 10,263 Cr
23.9%
Net Profit (Q2 FY27)
₹ 1,124 Cr
32.5%
EBITDA (Q2 FY27)
₹ 2,156 Cr
28.5%
Reported EPS (Q2 FY27)
19.57
33.9%
🏢 How This Affects the Company
📈
Business Impact
The completion of the Lannett acquisition strengthens Aurobindo Pharma's US presence and expands its capabilities in complex and controlled substances. The launch of 10 new products, including gAdvair and ADQUEY, contributes to portfolio growth.
💰
Financial Impact
Revenue from operations increased by 23.9% year-on-year to ₹10,263 Cr. Net Profit attributable to owners grew 32.7% to ₹1,126 Cr. The company maintained a strong net cash position of ~US$ 189 million as of September 30, 2026.
⚙️
Operational Impact
The company's sustained profitability is reflected in the highest-ever quarterly EBITDA of ₹2,156 Cr. Net Capex of US$ 89 million was primarily directed towards capability enhancements and new business developments.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this earnings presentation.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Ltd are affected by the company's financial performance, which showed a 32.7% increase in Net Profit attributable to owners in Q2 FY27 to ₹1,126 Cr.
🔍
Management Signal
The financial results and business highlights indicate management's focus on revenue growth across segments, profitability improvement, strategic acquisitions, and new product development.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — observe sustained revenue and profit growth trends.
Update on biosimilars and biologics contract manufacturing development pipeline.
Further details on integration of Lannett acquisition and its business contributions.
LOW RISK The filing indicates strong financial performance and strategic business developments.
💡 Investor Takeaway
Aurobindo Pharma reported Q2 FY27 Net Profit of ₹1,124 Cr, up 32.5% year-on-year from ₹848 Cr in Q2 FY26. Revenue from operations grew 23.9% to ₹10,263 Cr from ₹8,286 Cr. EBITDA reached ₹2,156 Cr at a 21.0% margin.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Net Profit attributable to owners increased 32.7% year-on-year to ₹1,126 Cr from ₹848 Cr in Q2 FY26.
  • Highest-ever quarterly revenue of ₹10,263 Cr, up 23.9% year-on-year, driven by broad business area growth.

⚠️ Concerns

  • Fx Gain/(Loss) decreased by 94.6% quarter-on-quarter to ₹3 Cr in Q2 FY27 from ₹53 Cr in Q1 FY27.
  • Share of Profit/(Loss) of JV reported a loss of ₹3 Cr in Q2 FY27 compared to a profit of ₹2 Cr in Q2 FY26.
📅 Company Track Record
Aurobindo Pharma's Q2 FY27 Net Profit of ₹1,124 Cr follows Q1 FY27 Net Profit of INR 1,032 Cr and Q2 FY26 Net Profit of INR 848 Cr, demonstrating a consistent upward trend in recent quarters. The company declared an interim dividend of Rs. 7.00 in Q2 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Aurobindo Pharma's Net Profit for Q2 FY27?
Aurobindo Pharma reported a Net Profit of ₹1,124 Cr for Q2 FY27, which is a 32.5% increase compared to ₹848 Cr in Q2 FY26.
What was Aurobindo Pharma's Revenue from Operations in Q2 FY27?
Revenue from Operations for Aurobindo Pharma in Q2 FY27 was ₹10,263 Cr, marking a 23.9% year-on-year growth from ₹8,286 Cr in Q2 FY26.
What was Aurobindo Pharma's EBITDA in Q2 FY27?
Aurobindo Pharma achieved an EBITDA of ₹2,156 Cr in Q2 FY27, reflecting a 28.5% year-on-year growth and an EBITDA margin of 21.0%.
What was the reported EPS for Aurobindo Pharma in Q2 FY27?
The reported Earnings Per Share (EPS) for Aurobindo Pharma in Q2 FY27 was 19.57, showing a 33.9% increase from 14.61 in Q2 FY26.
What strategic acquisition did Aurobindo Pharma complete in Q2 FY27?
Aurobindo Pharma successfully completed the acquisition of Lannett, aimed at strengthening its US presence and expanding capabilities in complex and controlled substances.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.